The Phase III trial sponsored by the Jonsson Comprehensive Cancer Center aims to evaluate the efficacy of dalteparin in preventing catheter-related complications in cancer patients undergoing chemotherapy. If successful, this study could position dalteparin as a standard preventive treatment in oncology settings, potentially expanding its market share in the anticoagulant segment. Given the high incidence of catheter-related complications in cancer patients, the commercial opportunity is significant. However, competitive products and alternative therapies in the anticoagulation market must be considered during diligence, particularly those targeting similar patient populations.